Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati
A phase 3 trial of Zongertinib, Pembrolizumab, Atezolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.
Overview
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations is a phase 3 interventional study registered as NCT07195695 by Boehringer Ingelheim, with 400 participants planned, started 2026-01-16 and due to reach its primary completion in 2032-02-26. Interventions recorded: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Shares Zongertinib, Boehringer Ingelheim, Pembrolizumab, Non-small-cell lung cancer.
- TrialBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Shares Zongertinib, Boehringer Ingelheim, Pembrolizumab, Non-small-cell lung cancer.
- TrialBeamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Shares Zongertinib, Boehringer Ingelheim.
- TrialBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Shares Atezolizumab, Nivolumab, Pembrolizumab, Small-cell lung cancer.
- TrialDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment
Shares Boehringer Ingelheim, Atezolizumab, Small-cell lung cancer.
- TrialQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Shares Atezolizumab, Durvalumab, Nivolumab, Pembrolizumab.
- TrialEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL
Shares Atezolizumab, Durvalumab, Nivolumab, Small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.